Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics
←Back to story

FDA Grants Accelerated Approval to Neladalkib for ALK-Positive NSCLC

MedscapeView source article

Part of story

FDA approves GSK's neladalkib for ALK-positive non-small cell lung cancer

The FDA granted accelerated approval to neladalkib (Nelkarmi), a kinase inhibitor from Nuvalent acquired by GSK, for adults with locally advanced or metastatic ALK-positive non-small cell lung cancer who have previously been treated.

Nov 17, 2026·2 sourcesAccelerated approval pathwaysDrug Policy, Pricing & ApprovalFDA drug approvalTargeted cancer therapyCancer and Cancer TreatmentPharmaceutical IndustryClinical trialsCancer & OncologyCancer treatment
FDA approves GSK's neladalkib for ALK-positive non-small cell lung cancer
00

Other sources for this story

The Wall Street Journal

GSK Gets FDA Approval for New Lung-Cancer Drug